Peptide Compounds For Treating Refractory Status Epilepticus

Patent No. EP2035029 (titled "Peptide Compounds For Treating Refractory Status Epilepticus") was filed by Schwarz Pharma on Jun 15, 2007. The application was issued on Nov 30, 2016.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ACCORD HEALTHCAREAug 30, 2017TER MEER UND PARTNER
PENTAFARMAAug 30, 2017WEIST
STADA ARZNEIMITTELAug 30, 2017HAMM&WITTKOPP PATENTANWÄLTE PARTMBB
COOKEAug 29, 2017ELKINGTON AND FIFE
HEXALAug 28, 2017BEST

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2035029

SCHWARZ PHARMA
Application Number
EP07764678A
Filing Date
Jun 15, 2007
Status
Revoked
Jul 12, 2019
Publication Date
Nov 30, 2016